BMS cancer drug’s expanded approval gives it an edge over a Gilead cell therapy

BMS cancer drug’s expanded approval gives it an edge over a Gilead cell therapy

A Bristol Myers Squib cancer drug made by engineering a patient’s own immune cells is now approved to treat patients in earlier stages of their disease, a regulatory decision that expands the number of patients that can be reached with this type of personalized cell therapy. The decision could also give BMS an edge over … Read more

Startups must warm up to provider workflows to create effective tech, healthcare CIO says

Startups must warm up to provider workflows to create effective tech, healthcare CIO says

The myriad of inefficiencies in the US healthcare system continues to contribute to the declining retention rates spirit burnout crisis affecting its workforce. Startups are eager to step in and create technology to address these inefficiencies, but these efforts often end up producing more hype than meaningful solutions, said David Chou, chief information officer at … Read more

Ipsen’s $ 247M Epizyme acquisition brings approved cancer drug & more in pipeline

Ipsen’s $ 247M Epizyme acquisition brings approved cancer drug & more in pipeline

Ipsen has been reshaping its drug lineup by striking deals and its latest one is a $ 247 million agreement to acquire Epizyme, a cancer drug developer with one commercialized product and a pipeline of additional therapeutic candidates. The key piece of the acquisition is Tazverik, a third-line treatment for follicular lymphoma. While that drug … Read more

How health systems can successfully manage and grow their provider networks with an EHR

How health systems can successfully manage and grow their provider networks with an EHR

Against the backdrop of the pandemic, the preferences and expectations of healthcare consumers have changed significantly over the last two years. One of the most profound changes taking place is that patients are now prioritizing convenience and access to care above all else. As a result, health systems are investing heavily in digital transformation initiatives … Read more

Flawed design is why hospitals are not complying with price transparency rules

Flawed design is why hospitals are not complying with price transparency rules

“How do you create a spreadsheet or database with 50,000 rows of highly technical, clinical billing information consumer-friendly?” That is the question Niall Brennan posed in a recent interview following the first stinging fine that the Centers for Medicare and Medicaid Services levied on a health system in Atlanta. Having served as CMS ‘chief data … Read more

Convergence of medtech and health tech: Helping providers plan procedures and easing patient anxiety

Convergence of medtech and health tech: Helping providers plan procedures and easing patient anxiety

One of the fascinating aspects of medtech is not only how it can be harnessed by physicians to improve collaboration and planning around a procedure, but also how it can be deployed to help patients understand complex medical procedures and reduce their anxiety. The convergence of med tech and health tech is transforming how providers … Read more

Report: Doctors want health systems to be more involved in maintaining their digital provider profiles

Report: Doctors want health systems to be more involved in maintaining their digital provider profiles

Americans ‘search for the right provider often begins with browsing physicians’ online profiles, the way one might look for a new hairstylist or plumber. These digital profiles – such as those found on a health system’s website, health plan directory or third-party healthcare website like Zocdoc or Healthgrades – must be robust in order to … Read more

How small biotech companies can make the most out of today’s deal-making landscape

How small biotech companies can make the most out of today’s deal-making landscape

Deal-making in oncology remains a hot area, primarily driven by the immuno-oncology space. The year 2020 was a landmark year for investment in biotech and pharma, with oncology generating a large portion of the deal-making ($ 133 billion). In 2021, oncology-focused deals accounted for a large proportion of global biopharma licensing, collaborations, and joint venture … Read more

A myopic approach to merger regulation fails consumers instead of protecting them

A myopic approach to merger regulation fails consumers instead of protecting them

We are beginning the end game of healthcare consolidation. Over the past decade, we’ve seen a burst of activity in healthcare mergers. At this point, most of the smaller, attractive provider organizations have been acquired by the bigger players. The current landscape is dominated by larger healthcare delivery entities, and in their search for acquisitions … Read more

Thought partnerships: The new frontier of client-agency partnerships

Thought partnerships: The new frontier of client-agency partnerships

Much has been said about how to maximize client-agency relationships, particularly in biopharma. Beyond offering helpful tips and advice for managing these relationships (ie, be transparent, flexible, empathetic, etc.), a broader conversation is asking to be had. The landscape we find ourselves in has changed — not just for the healthcare practitioners and patients we … Read more